BVS Economia da Saúde

Innovative mechanisms of pre-marketing authorization access for rare diseases in Brazil: a case study of pabinafusp-alfa for mucopolysaccharidosis type II

Patients with rare diseases frequently face unmet medical needs due to the high costs, lengthy development times, and slow approval processes for new treatments. This case study discusses innovative access alternatives for rare diseases in Brazil, focusing on early access to pabinafusp-alfa for mucopolys...

Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective

Magro, Frederico José Bighetti; Barbosa, Aline; Taminato, Alexandre; Migliavaca, Celina Borges; Federico, Priscila; Tebyriçá, Renata Nahuys; Cançado, Jose Eduardo D; Giavina-Bianchi, Pedro; Falavigna, Maicon.

J. bras. econ. saúde (Impr.); 14 (3), 2022

Objective: To compare the costs of dupilumab and omalizumab for treating severe allergic asthma patients from the perspective of the Brazilian private healthcare system. Methods: Using clinical and demographic inputs from the literature, we simulated a cohort of 5,000 severe allergic asthma patients and ...

Asma, Custos e Análise de Custo, Omalizumab

Texto completo

Resultados: 2

Innovative mechanisms of pre-marketing authorization access for rare diseases in Brazil: a case study of pabinafusp-alfa for mucopolysaccharidosis type II

Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective

Queremos sua opinião!